Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Carbinoxamine
2. Histex Ct
3. Histex I-e
4. Histex Pd
1. 3505-38-2
2. Carbinoxamine Maleate Salt
3. Lergefin
4. Clistin
5. Ciberon
6. Cliston
7. P-carbinoxamine Maleate
8. Allergefon Maleate
9. Paracarbinoxamine Maleate
10. Nsc-62362
11. Chebi:31353
12. 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine Maleate
13. Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-n,n-dimethyl-, (z)-2-butenedioate (1:1)
14. 02o55696wh
15. 3505-38-2 (carbinoxamine Maleate)
16. Hislosine
17. Ziriton
18. Histine Sirup
19. Polistin T-caps
20. 2-((4-chlorophenyl)(pyridin-2-yl)methoxy)-n,n-dimethylethan-1-amine Maleate
21. Polistine T-caps
22. Dsstox_cid_27805
23. Dsstox_rid_82573
24. Dsstox_gsid_47828
25. Carbinoxamine Hydrogen Maleate
26. Arbinoxa
27. {2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]ethyl}dimethylamine Maleate
28. Clistine Maleate
29. Clistin-d
30. Karbinal Er
31. (z)-but-2-enedioic Acid;2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-n,n-dimethylethanamine
32. Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-n,n-dimethyl-, (2z)-2-butenedioate (1:1)
33. Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-n,n-dimethyl-, (2z)-2-butenedioate (1:1)
34. Component Of Clistin-d
35. Sr-01000736676
36. Ncgc00166141-01
37. Einecs 222-498-0
38. Nsc 62362
39. Clistin Maleate
40. Unii-02o55696wh
41. Carbinoxamine Maleate [usp:jan]
42. Prestwick_238
43. Arbinoxamine Maleate
44. Clistin (tn)
45. Karbinal Er (tn)
46. 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-n,n-dimethylethanamine Maleate
47. Carbinoxamine (maleate)
48. Carbinoxaminemaleate
49. 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine Bimaleate
50. 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine Maleate (1:1)
51. Cas-3505-38-2
52. Schembl97703
53. Spectrum1500161
54. Chembl1200974
55. Dtxsid0047828
56. Hms502i21
57. Hy-b1589a
58. Carbinoxamine Maleate (jan/usp)
59. Carbinoxamine Maleate [mi]
60. Hms1570b03
61. Hms1920i21
62. Hms2091a04
63. Hms2097b03
64. Hms3259g22
65. Hms3714b03
66. Hms3885f18
67. Pharmakon1600-01500161
68. Carbinoxamine Maleate [jan]
69. Bcp28449
70. Nsc62362
71. Tox21_112336
72. Carbinoxamine Maleate [vandf]
73. Ccg-40113
74. Mfcd00050923
75. Nsc756670
76. S4696
77. Carbinoxamine Maleate [mart.]
78. Wln: Qv1u1vq -c &621
79. Akos015962162
80. Carbinoxamine Maleate [usp-rs]
81. Carbinoxamine Maleate [who-dd]
82. Tox21_112336_1
83. Ac-5508
84. Cs-8018
85. Nc00602
86. Nsc-756670
87. Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-n,n-dimethyl-,(2z)-2-butenedioate (1:1)
88. Pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)-, Maleate (1:1)
89. Ncgc00095302-01
90. Ncgc00166141-06
91. Bs-43784
92. Carbinoxamine Maleate [orange Book]
93. Carbinoxamine Maleate [usp Monograph]
94. Carbinoxamine Maleate Salt, Analytical Standard
95. D01336
96. Ethanamine,n-dimethyl-, (z)-2-butenedioate (1:1)
97. Sr-01000736676-2
98. Sr-01000736676-3
99. Q27114280
100. 2-[p-chloro-.alpha.-[2-(dimethylamino)ethoxy]benzyl]pyridine Bimaleate
101. 2-[p-chloro-.alpha.-[2-(dimethylamino)ethoxy]benzyl]pyridine Maleate
102. Carbinoxamine Maleate, United States Pharmacopeia (usp) Reference Standard
103. 2-(p-chloro-.alpha.-(2-(dimethylamino)ethoxy)benzyl)pyridine Maleate (1:1)
104. 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-n,n-dimethylethanamine (2z)-but-2-enedioate
Molecular Weight | 406.9 g/mol |
---|---|
Molecular Formula | C20H23ClN2O5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 8 |
Exact Mass | 406.1295495 g/mol |
Monoisotopic Mass | 406.1295495 g/mol |
Topological Polar Surface Area | 100 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 386 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Carbinoxamine maleate |
Drug Label | Carbinoxamine maleate is a histamine-H1 receptor blocking agent.Each 5 mL (teaspoonful) of oral solution contains 4 mg carbinoxamine maleate and the following inactive ingredients: artificial bubble gum flavor, citric acid (anhydrous), glycerin, meth... |
Active Ingredient | Carbinoxamine maleate |
Dosage Form | Tablet; Solution |
Route | oral; Oral |
Strength | 4mg; 4mg/5ml |
Market Status | Prescription |
Company | Vintage Pharms; Cypress Pharm; Lynrose Labs; Mikart; Invagen Pharms |
2 of 4 | |
---|---|
Drug Name | Karbinal er |
PubMed Health | Carbinoxamine (By mouth) |
Drug Classes | Cold/Cough Agent, Respiratory Agent |
Drug Label | Each 5 mL of Karbinal ER Extended-release Oral Suspension contains carbinoxamine complexed with polistirex equivalent to 4 mg carbinoxamine maleate and the following inactive ingredients: citric acid anhydrous, strawberry-banana flavor, glycerin, hig... |
Active Ingredient | Carbinoxamine maleate |
Dosage Form | Suspension, extended release |
Route | Oral |
Strength | 4mg/5ml |
Market Status | Prescription |
Company | Tris Pharma |
3 of 4 | |
---|---|
Drug Name | Carbinoxamine maleate |
Drug Label | Carbinoxamine maleate is a histamine-H1 receptor blocking agent.Each 5 mL (teaspoonful) of oral solution contains 4 mg carbinoxamine maleate and the following inactive ingredients: artificial bubble gum flavor, citric acid (anhydrous), glycerin, meth... |
Active Ingredient | Carbinoxamine maleate |
Dosage Form | Tablet; Solution |
Route | oral; Oral |
Strength | 4mg; 4mg/5ml |
Market Status | Prescription |
Company | Vintage Pharms; Cypress Pharm; Lynrose Labs; Mikart; Invagen Pharms |
4 of 4 | |
---|---|
Drug Name | Karbinal er |
PubMed Health | Carbinoxamine (By mouth) |
Drug Classes | Cold/Cough Agent, Respiratory Agent |
Drug Label | Each 5 mL of Karbinal ER Extended-release Oral Suspension contains carbinoxamine complexed with polistirex equivalent to 4 mg carbinoxamine maleate and the following inactive ingredients: citric acid anhydrous, strawberry-banana flavor, glycerin, hig... |
Active Ingredient | Carbinoxamine maleate |
Dosage Form | Suspension, extended release |
Route | Oral |
Strength | 4mg/5ml |
Market Status | Prescription |
Company | Tris Pharma |
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-12-18
Pay. Date : 2020-11-12
DMF Number : 34110
Submission : 2019-08-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21301
Submission : 2008-01-31
Status : Active
Type : II
Date of Issue : 2019-08-16
Valid Till : 2025-08-15
Written Confirmation Number : WC-0022
Address of the Firm :
NDC Package Code : 50370-0006
Start Marketing Date : 2010-04-13
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-03-06
Pay. Date : 2014-03-04
DMF Number : 9844
Submission : 1992-08-28
Status : Active
Type : II
NDC Package Code : 12294-0056
Start Marketing Date : 1993-08-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21335
Submission : 2008-02-14
Status : Active
Type : II
NDC Package Code : 66022-0121
Start Marketing Date : 2013-03-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33626
Submission : 2019-11-04
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3207
Submission : 1978-04-28
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8687
Submission : 1990-08-03
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2962
Submission : 1977-06-06
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21283
Submission : 2008-01-15
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-03-06
Pay. Date : 2014-03-04
DMF Number : 9844
Submission : 1992-08-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21301
Submission : 2008-01-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-12-18
Pay. Date : 2020-11-12
DMF Number : 34110
Submission : 2019-08-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21335
Submission : 2008-02-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21283
Submission : 2008-01-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2962
Submission : 1977-06-06
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33626
Submission : 2019-11-04
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3207
Submission : 1978-04-28
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8687
Submission : 1990-08-03
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Carbinoxamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carbinoxamine, including repackagers and relabelers. The FDA regulates Carbinoxamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carbinoxamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carbinoxamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Carbinoxamine supplier is an individual or a company that provides Carbinoxamine active pharmaceutical ingredient (API) or Carbinoxamine finished formulations upon request. The Carbinoxamine suppliers may include Carbinoxamine API manufacturers, exporters, distributors and traders.
click here to find a list of Carbinoxamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Carbinoxamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Carbinoxamine active pharmaceutical ingredient (API) in detail. Different forms of Carbinoxamine DMFs exist exist since differing nations have different regulations, such as Carbinoxamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Carbinoxamine DMF submitted to regulatory agencies in the US is known as a USDMF. Carbinoxamine USDMF includes data on Carbinoxamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carbinoxamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Carbinoxamine suppliers with USDMF on PharmaCompass.
A Carbinoxamine written confirmation (Carbinoxamine WC) is an official document issued by a regulatory agency to a Carbinoxamine manufacturer, verifying that the manufacturing facility of a Carbinoxamine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Carbinoxamine APIs or Carbinoxamine finished pharmaceutical products to another nation, regulatory agencies frequently require a Carbinoxamine WC (written confirmation) as part of the regulatory process.
click here to find a list of Carbinoxamine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carbinoxamine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Carbinoxamine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Carbinoxamine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Carbinoxamine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carbinoxamine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Carbinoxamine suppliers with NDC on PharmaCompass.
Carbinoxamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Carbinoxamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Carbinoxamine GMP manufacturer or Carbinoxamine GMP API supplier for your needs.
A Carbinoxamine CoA (Certificate of Analysis) is a formal document that attests to Carbinoxamine's compliance with Carbinoxamine specifications and serves as a tool for batch-level quality control.
Carbinoxamine CoA mostly includes findings from lab analyses of a specific batch. For each Carbinoxamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Carbinoxamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Carbinoxamine EP), Carbinoxamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carbinoxamine USP).
LOOKING FOR A SUPPLIER?